Trial · NCT02586155
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE | 120 weeks | events | NUMBER | |
| SECONDARY | Incidence of First Occurrence of Adjudication-confirmed Broadly Defined MACE | 120 weeks | events | NUMBER | |
| SECONDARY | Incidence of Hospitalization for Congestive Heart Failure (CHF) | 120 weeks | events | NUMBER | |
| SECONDARY | Incidence of All-cause Mortality | 120 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Change in Apolipoprotein A1 (ApoA-I) Concentration From Baseline Over Time Within and Between Treatment Groups | 120 weeks | A select subset of subjects were analyzed for ApoA-I, Subject data is missing across time points. | mg/dL | MEDIAN |
| SECONDARY | Change in Apolipoprotein B (apoB) Concentration From Baseline Over Time Within and Between Treatment Groups | 120 weeks | A select subset of subjects were analyzed for ApoB, Subject data is missing across time points. | mg/dL | MEDIAN |
| SECONDARY | Change in LDL-C Concentration From Baseline Over Time Within and Between Treatment Groups | 120 weeks | All subjects were analyzed and contributed LDL-C data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms.~Subject data is missing across time points. | mmol/L | MEDIAN |
| SECONDARY | Change in HDL-C Concentration From Baseline Over Time Within and Between Treatment Groups | 120 weeks | All subjects were analyzed and contributed HDL-C data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms.~Subject data is missing across time points. | mmol/L | MEDIAN |
| SECONDARY | Change in Triglyceride (TG) Concentration From Baseline Over Time Within and Between Treatment Groups | 120 weeks | All subjects were analyzed and contributed TG data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms.~Subject data is missing across time points. | mmol/L | MEDIAN |
| SECONDARY | Change in Hemoglobin (Hb) A1c From Baseline Over Time Within and Between Treatment Groups | 120 weeks | All subjects were analyzed and contributed HbA1c data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms Subject data is missing across time points | % of hemoglobin | MEDIAN |
| SECONDARY | Change in Glucose From Baseline Over Time Between and Within Treatment Groups | 120 weeks | All subjects were analyzed and contributed glucose data for the 'High-Intensity Statin Therapy + RVX000222' and the 'High-Intensity statin therapy + Placebo' arms.~Subject data is missing across time points | mmol/L | MEDIAN |
| SECONDARY | Change in Alkaline Phosphatase (ALP) From Baseline Over Time Within and Between Treatment Groups | 172 weeks | Subject data is missing across time points | U/L | MEDIAN |
| SECONDARY | Change in C Reactive Protein (CRP) Concentration From Baseline Over Time Within and Between Treatment Groups | 52 weeks | A select subset of subjects in two countries were analyzed for CRP, Subject data is missing across time points. | mg/dL | MEDIAN |
| SECONDARY | Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline Over Time Within and Between Treatment Groups for Subjects With Impaired Renal Function at Baseline (eGFR <60 mL/Min/1.7m2) | 120 weeks | Subject data is missing across time points | ml/min | MEDIAN |
| POST_HOC | Incidence of First Occurrence of Adjudication-Confirmed Four-Point MACE | 120 weeks | events | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02586155/outcomes